克拉斯
合成致死
突变体
癌症研究
医学
突变
胰腺癌
作者
K. Briggs,G. Corriea,A. Tsai,M. Zhang,M.R. Tonini,E.W. Wilker,C.B. Davis,K.M. Cottrell,J.P. Maxwell,A. Huang
标识
DOI:10.1016/j.annonc.2022.01.032
摘要
MTAP deletion is one of the most common genetic alterations in human cancer, occurring in more than 10% of lung and pancreatic adenocarcinomas. PRMT5 dependence in cells with MTAP deletions is a strong and prevalent synthetic lethal interaction. TNG908 has a novel MTA-cooperative binding mechanism that drives synthetic lethality with MTAP deletion, unlike PRMT5 inhibitors currently in clinical development, and is 15X selective for MTAPnull over MTAPWT cells. Approximately 30% of MTAPnull lung adenocarcinomas and 85% of MTAPnull pancreatic adenocarcinomas are also KRAS-mutant.
科研通智能强力驱动
Strongly Powered by AbleSci AI